Improving Treatment Outcome In Paediatric Acute Lymphoblastic Leukaemia By Minimal Residual Disease Detection And Pharmacokinetics
Funder
National Health and Medical Research Council
Funding Amount
$609,759.00
Summary
The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and pharmacokinetic testing to determine the effectiveness of a key chemotherapy drug (PEG-L-Asparaginase) in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.
Sortase Peptide Technology: Enzymatic Site-specific Bioconjugation To Improve Antibody Drug Conjugate Production And Performance
Funder
National Health and Medical Research Council
Funding Amount
$402,046.00
Summary
Cancer is characterised by uncontrolled cell growth, leading to invasion and destruction of adjacent tissues. It is a major cause of death in Australia. Targeted drug delivery is an attractive therapeutic strategy that has the potential to lower systemic drug concentrations and reduce side effects. We are developing more efficient cancer drugs.
Improving Risk Evaluation And Outcomes In Paediatric Acute Lymphoblastic Leukaemia
Funder
National Health and Medical Research Council
Funding Amount
$798,022.00
Summary
The main objective of this project is to make substantial improvements in the treatment of patients with childhood leukaemia by greater use of molecular diagnostics to measure minimal residual disease (MRD) and high risk genetic changes in Australian patients enrolled on an international clinical trial which has been designed to reduce the incidence of both relapses and long term side-effects.